Document is current
Any future updates will be listed below
-
Authors
Ho, Ching-Huang https://orcid.org/0000-0001-8359-8068
Dippel, Maxwell A.
McQuade, Meghan S.
Nguyen, LeAnn P.
Mishra, Arpit
Pribitzer, Stephan
Hardy, Samantha
Chandok, Harshpreet
Chardon, Florence M. https://orcid.org/0000-0001-8858-989X
McDiarmid, Troy A.
DeBerg, Hannah A. https://orcid.org/0000-0002-5263-158X
Buckner, Jane H. https://orcid.org/0000-0002-9005-1885
Shendure, Jay https://orcid.org/0000-0002-1516-1865
de Boer, Carl G. https://orcid.org/0000-0001-8935-5921
Guo, Michael H.
Tewhey, Ryan https://orcid.org/0000-0002-4607-8001
Ray, John P. https://orcid.org/0000-0001-7294-4260
- License Information
-
More Information
Article History
Received: 15 September 2024
Accepted: 18 July 2025
First Online: 18 September 2025
Competing interests
: R.T. holds patents related to the application of MPRA. J.S. is a scientific advisory board member, consultant and/or co-founder of Cajal Neuroscience, Guardant Health, Maze Therapeutics, Camp4 Therapeutics, Phase Genomics, Adaptive Biotechnologies, Scale Biosciences, Sixth Street Capital, Pacific Biosciences, Somite Theraputics and Prime Medicine. J.H.B. is a Scientific Co-Founder and Scientific Advisory Board member of GentiBio, a consultant for Bristol Myers Squibb and Moderna and has past and current research projects sponsored by Amgen, Bristol Myers Squibb, Janssen, Novo Nordisk and Pfizer. J.H.B. also has a patent for tenascin-C autoantigenic epitopes in rheumatoid arthritis. The other authors declare no competing interests.
